ADR Biomedical Holdings Inc.

As of March 31, 2026, ADR Biomedical Holdings Inc. carries a market capitalization of 7.27B, placing it among publicly traded companies globally. Its enterprise value stands at 7.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ADR Biomedical Holdings Inc.'s next confirmed earnings release is scheduled for November 13, 2026.

As of March 31, 2026, ADR Biomedical Holdings Inc. has 8.93M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, ADR Biomedical Holdings Inc. maintains a current ratio of 1.55, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, ADR Biomedical Holdings Inc.'s stock has declined approximately 11.29% over the past 52 weeks. The 50-day moving average sits at 799.32, while the 200-day moving average is 823.28.

As of March 31, 2026, ADR Biomedical Holdings Inc. holds 125.90M in cash and equivalents against - - in total debt, resulting in a net debt position of -125.90M. Total book value stands at 22.03M, with working capital of 123.79M providing operational flexibility.

ADR Biomedical Holdings Inc.'s most recent stock split took place on January 29, 2018 with a 1:5 split ratio.